Natera, Inc. (NTRA)
NASDAQ: NTRA · Real-Time Price · USD
140.12
+3.55 (2.60%)
Aug 5, 2025, 4:00 PM - Market closed
Natera Revenue
Natera had revenue of $501.83M in the quarter ending March 31, 2025, with 36.46% growth. This brings the company's revenue in the last twelve months to $1.83B, up 51.50% year-over-year. In the year 2024, Natera had annual revenue of $1.70B with 56.75% growth.
Revenue (ttm)
$1.83B
Revenue Growth
+51.50%
P/S Ratio
9.81
Revenue / Employee
$412,945
Employees
4,434
Market Cap
19.13B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.70B | 614.34M | 56.75% |
Dec 31, 2023 | 1.08B | 262.35M | 31.99% |
Dec 31, 2022 | 820.22M | 194.74M | 31.13% |
Dec 31, 2021 | 625.49M | 234.48M | 59.97% |
Dec 31, 2020 | 391.01M | 88.68M | 29.33% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
NTRA News
- 4 days ago - Natera Highlights Latest Prospera™ Data at WTC 2025; 16 Abstracts Including Five Oral Presentations - Business Wire
- 5 days ago - Natera to Report Its Second Quarter Results on August 7, 2025 - Business Wire
- 7 days ago - Natera Announces Launch of ABCSG 61 (“TEODOR”), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer - Business Wire
- 12 days ago - PEDAL Study Successful, Shows Monitoring with Prospera™ Kidney Provides Accurate Prognosis of Long-Term Clinical Outcomes Following Rejection; Now Published in AJT - Business Wire
- 4 weeks ago - Natera Presents Data at ESMO GI on its Tissue-Free Latitude™ MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer - Business Wire
- 5 weeks ago - Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD - Business Wire
- 2 months ago - Natera Announces Medicare Coverage for Signatera™ Genome - Business Wire
- 2 months ago - SignateraTM Genome Clinical Performance Highlighted at ASCO 2025 - Business Wire